Sandy Spring Bank’s Intellia Therapeutics NTLA Stock Holding History

Sandy Spring Bank’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$15	Hold	2	–	–	﹤0.01%	1211
2024 Q4	$24	Hold	2	–	–	﹤0.01%	1198
2024 Q3	$42	Hold	2	–	–	﹤0.01%	1183
2024 Q2	$45	Hold	2	–	–	﹤0.01%	1255
2024 Q1	$56	Sell	2 -100	-98%	-$2.78K	﹤0.01%	1219
2023 Q4	$3.11K	Buy	102 +100	+5,000%	+$2.87K	﹤0.01%	972
2023 Q3	$64	Hold	2	–	–	﹤0.01%	1165
2023 Q2	$82	Hold	2	–	–	﹤0.01%	1205
2023 Q1	$75	Sell	2 -104	-98%	-$4.08K	﹤0.01%	1143
2022 Q4	$3.7K	Buy	+106	New	+$5.04K	﹤0.01%	964
2019 Q2	–	Sell	-1,000	Closed	-$17K	–	845
2019 Q1	$17K	Hold	1,000	–	–	﹤0.01%	607
2018 Q4	$14K	Hold	1,000	–	–	﹤0.01%	625
2018 Q3	$29K	Hold	1,000	–	–	﹤0.01%	539
2018 Q2	$27K	Hold	1,000	–	–	﹤0.01%	546
2018 Q1	$21K	Buy	+1,000	New	+$24.6K	﹤0.01%	599

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sandy Spring Bank's NTLA Position: Q1 2025 in Review

Sandy Spring Bank held its Intellia Therapeutics (NTLA) position steady in Q1 2025 at 2 shares worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #1211.

Sandy Spring Bank first reported a position in NTLA in Q1 2018 and has held it in 15 quarters since. The position peaked at $29K in Q3 2018. 295 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

Sandy Spring Bank held 2 shares of Intellia Therapeutics worth $15 as of Q1 2025.
Sandy Spring Bank left its Intellia Therapeutics share count unchanged in Q1 2025.
Intellia Therapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #1211 holding.
Sandy Spring Bank first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 15 quarters since.
Sandy Spring Bank's Intellia Therapeutics position peaked at $29K in Q3 2018.
295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.